Abemaciclib (Verzenio®) in combination with a nonsteroidal aromatase inhibitor (NSAI) as initial therapy for advanced breast cancer (ABC)
McGahan L
Record ID 32018000202
English
Authors' recommendations:
Overall, abemaciclib with endocrine therapy substantially reduces the risk of disease progression and increases ORR versus ET alone as initial therapy for HR-positive, HER2-negative ABC in postmenopausal women. OS and QoL data are needed to confirm that patients achieve a clinically relevant benefit over time in the context of increasing toxicity. Biomarker trials that track cellular proliferation and evaluate Rb protein and ER activity may help to identify which patients benefit most from adding abemaciclib as initial treatment. As there are no comparative trials, differences in the safety profiles of CDK4/6 inhibitors may assist physicians in selecting the most appropriate CDK4/6 inhibitor to meet individual patient needs.
Details
Project Status:
Completed
URL for project:
https://hta.lbg.ac.at/page/horizon-scanning-in-der-onkologie/en
Year Published:
2018
URL for published report:
http://eprints.hta.lbg.ac.at/1154/1/DSD_HSO_Nr.78.pdf
URL for additional information:
http://eprints.hta.lbg.ac.at/1154/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Austria
MeSH Terms
- Aminopyridines
- Aromatase Inhibitors
- Benzimidazoles
- Breast
- Breast Neoplasms
- Humans
Contact
Organisation Name:
Ludwig Boltzmann Institute for Health Technology Assessment
Contact Address:
Ludwig Boltzmann Institute for fuer Health Technology Assessment (LBI-HTA), Garnisongasse 7/rechte Stiege Mezzanin (Top 20), 1090 Vienna, Austria. Tel: +43 1 236 8119 - 0 Fax: +43 1 236 8119 - 99
Contact Name:
tarquin.mittermayr@aihta.at
Contact Email:
office@aihta.at
Copyright:
Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.